BDP8900

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 563969

CAS#: 2226507-05-5

Description: BDP8900 is a potent and selective MRCK inhibitor, reducing substrate phosphorylation. BDP8900 leads to morphological changes in cancer cells along with inhibition of their motility and invasive character.


Price and Availability

Size
Price

Size
Price

Size
Price

BDP8900 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 563969
Name: BDP8900
CAS#: 2226507-05-5
Chemical Formula: C19H23N5S
Exact Mass: 353.1674
Molecular Weight: 353.49
Elemental Analysis: C, 64.56; H, 6.56; N, 19.81; S, 9.07


Synonym: BDP8900; BDP-8900; BDP 8900

IUPAC/Chemical Name: (S)-2-(4-(1,8-Diazaspiro[5.5]undecan-8-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)thiazole

InChi Key: AZYKATVQZWSITP-IBGZPJMESA-N

InChi Code: InChI=1S/C19H23N5S/c1-2-7-23-19(5-1)6-3-10-24(13-19)15-4-8-20-17-16(15)14(12-22-17)18-21-9-11-25-18/h4,8-9,11-12,23H,1-3,5-7,10,13H2,(H,20,22)/t19-/m0/s1

SMILES Code: C1(C2=CNC3=NC=CC(N(CCC4)C[C@@]54CCCCN5)=C32)=NC=CS1


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
2934.99.03.00


References

1: Unbekandt M, Belshaw S, Bower J, Clarke M, Cordes J, Crighton D, Croft DR, Drysdale MJ, Garnett MJ, Gill K, Gray C, Greenhalgh DA, Hall JAM, Konczal J, Lilla S, McArthur D, McConnell P, McDonald L, McGarry L, McKinnon H, McMenemy C, Mezna M, Morrice NA, Munro J, Naylor G, Rath N, Schüttelkopf AW, Sime M, Olson MF. Discovery of Potent and Selective MRCK Inhibitors with Therapeutic Effect on Skin Cancer. Cancer Res. 2018 Apr 15;78(8):2096-2114. doi: 10.1158/0008-5472.CAN-17-2870. Epub 2018 Jan 30. PubMed PMID: 29382705; PubMed Central PMCID: PMC5901721.